Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Ipca Laboratories Limited
483
•Ipca Laboratories Limited•December 5, 2025

Ipca Laboratories Limited – FDA 483, Dec 5, 2025

Record Details

An FDA inspection conducted at Ipca Laboratories Limited from December 1 to December 5, 2025, identified three significant observations related to manufacturing practices for Active Pharmaceutical Ingredients (APIs) destined for the US market. The findings, detailed in an FDA 483 document, highlight deficiencies in facility maintenance, analytical test methods, and controls to prevent material cross-contamination.

Specifically, Observation 1 noted that manufacturing clean rooms were not adequately maintained to minimize potential contamination. Examples included significant peeling paint on ceilings and numerous cracks on walls and ceilings in areas where APIs are exposed, indicating a failure to address these issues despite routine facility inspections.

Observation 2 addressed deficiencies in the suitability of analytical test methods. The verification studies for HPLC assays and organic impurities were found to be inadequate, particularly regarding unvalidated column temperature ranges. This concern was underscored by a previous out-of-specification investigation that revealed issues with shifted peak retention times, questioning method reliability.

Finally, Observation 3 pointed to a lack of adequate controls to minimize residual material carryover between successive batches of the same API. The company's procedures did not establish a maximum duration for manufacturing campaigns, and no scientific data was provided to assure that residual materials from previous batches were not carried over into subsequent ones.

These observations indicate non-compliance with established Good Manufacturing Practices, requiring Ipca Laboratories Limited to implement comprehensive corrective and preventive actions to ensure product quality and safety, and formally respond to the FDA addressing each finding.

Company
Ipca Laboratories Limited
Inspection date
December 5, 2025
Product type
drugs
Office
Office of Inspections and Investigations
Person
  • Saleem A. Akhtar
View Company Profile

ID · 7a44d95c-6c13-40c5-92d3-1f09633151ed

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ipca Laboratories Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.